TOPLINE:

The use of SGLT2 inhibitors was associated with a reduced risk for atrial fibrillation (AF) in patients with type 2 diabetes (T2D).

METHODOLOGY:

SGLT2 inhibitors have been shown to provide therapeutic benefits to patients with heart failure and AF; however, data on their protective effect on AF in patients without heart failure are inconsistent.

Researchers conducted a retrospective case-control study in Germany to assess the association between the use of various antihyperglycemic medications between 2005 and 2023 and the diagnosis of AF in patients with T2D during the same period.

They used data from the Disease Analyzer database including 29,424 patients with T2D aged 40 years or older with an initial diagnosis of AF who were matched to an equal number of control patients

See Full Page